These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18605225)

  • 21. Natural products to drugs: natural product-derived compounds in clinical trials.
    Butler MS
    Nat Prod Rep; 2008 Jun; 25(3):475-516. PubMed ID: 18497896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Product quality considerations for mammalian cell culture process development and manufacturing.
    Gramer MJ
    Adv Biochem Eng Biotechnol; 2014; 139():123-66. PubMed ID: 23748351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Governance of natural health products regulation: an iterative process.
    Walji R; Wiktorowicz M
    Health Policy; 2013 Jun; 111(1):86-94. PubMed ID: 23523344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approaches in fostering quality parameters for medicinal botanicals in the Indian context.
    Gupta PD; Daswani PG; Birdi TJ
    Indian J Pharmacol; 2014; 46(4):363-71. PubMed ID: 25097272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence-based medicine, systematic reviews, and guidelines in interventional pain management: part 6. Systematic reviews and meta-analyses of observational studies.
    Manchikanti L; Datta S; Smith HS; Hirsch JA
    Pain Physician; 2009; 12(5):819-50. PubMed ID: 19787009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in biological source material.
    Robertson JS
    Biologicals; 2006 Mar; 34(1):61-3. PubMed ID: 16330224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality assurance of herbal raw materials in supply chain: challenges and opportunities.
    Govindaraghavan S
    J Diet Suppl; 2008; 5(2):176-212. PubMed ID: 22432433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug discovery and natural products: end of an era or an endless frontier?
    Li JW; Vederas JC
    Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
    Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M
    Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural health products and drug disposition.
    Foster BC; Arnason JT; Briggs CJ
    Annu Rev Pharmacol Toxicol; 2005; 45():203-26. PubMed ID: 15822175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical process research and development in the 21st century: challenges, strategies, and solutions from a pharmaceutical industry perspective.
    Federsel HJ
    Acc Chem Res; 2009 May; 42(5):671-80. PubMed ID: 19338294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of natural health products in treating osteoporosis: what is the quality of internet patient advice?
    Whelan AM; Jurgens TM; Bowles SK; Doyle H
    Ann Pharmacother; 2009 May; 43(5):899-907. PubMed ID: 19417114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M; Zhang D; Zhang H; Shyu WC
    Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development and perspectives of community DOTS].
    Narita T; Kobayashi N
    Kekkaku; 2009 Apr; 84(4):187-201. PubMed ID: 19425394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leishmaniasis: drug resistance and natural products (review).
    Polonio T; Efferth T
    Int J Mol Med; 2008 Sep; 22(3):277-86. PubMed ID: 18698485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New approaches in analyzing the pharmacological properties of herbal extracts.
    Hamburger M
    Proc West Pharmacol Soc; 2007; 50():156-61. PubMed ID: 18605255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of reagent standardization on the quality of diagnostic devices.
    Terrana B
    Med Device Technol; 1994; 5(6):18-21. PubMed ID: 10172086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.